ImevaX GmbH-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ImevaX GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014300
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImevaX GmbH (ImevaX) is a biopharmaceutical company that develops specific vaccines against chronic infections. The company identifies and uses immune modulatory bacterial factors to develop specific vaccines. It develops specific vaccines against pathogens that cause chronic infectious diseases. ImevaX is developing a vaccine against Helicobacter pylori that colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. ImevaX also develops vaccine that concentrates on prophylactic and therapeutic applications. The company also develops screening program that concentrates on infectious pathogens, which down-regulate the host immune system and develop immune evasion mechanisms. ImevaX is headquartered in Munich, Germany.

ImevaX GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ImevaX GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ImevaX GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ImevaX Raises Funds through Second Tranche of Series A Financing 10
ImevaX Raises USD9.5 Million in Series A Venture Financing 11
Partnerships 12
ProJect Pharmaceutics Enters into Development Agreement with ImevaX for IMX101 12
ImevaX GmbH – Key Competitors 13
ImevaX GmbH – Key Employees 14
ImevaX GmbH – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
ImevaX GmbH, Pharmaceuticals & Healthcare, Key Facts 2
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ImevaX GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ImevaX GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
ImevaX GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ImevaX Raises Funds through Second Tranche of Series A Financing 10
ImevaX Raises USD9.5 Million in Series A Venture Financing 11
ProJect Pharmaceutics Enters into Development Agreement with ImevaX for IMX101 12
ImevaX GmbH, Key Competitors 13
ImevaX GmbH, Key Employees 14

★海外企業調査レポート[ImevaX GmbH-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsui Chemicals, Inc.:企業の戦略・SWOT・財務情報
    Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ophthotech Corp (OPHT):製薬・医療:M&Aディール及び事業提携情報
    Summary Ophthotech Corp (Ophthotech) is a biopharmaceutical company that offers novel therapeutics to treat diseases of the back of the eye for age-related macular degeneration. The company’s products include Zimura, an anti-complemente is a central component of the complement cascade that is suppos …
  • SurModics Inc (SRDX)-医療機器分野:企業M&A・提携分析
    Summary SurModics Inc (SurModics) is a provider of device drug delivery coating and in vitro diagnostic technologies. The company offers wide range of advanced technologies that includes medical device coating technologies and surface modification coating technologies. Its technologies are employed …
  • Nisshin Seifun Group Inc:戦略・SWOT・企業財務分析
    Nisshin Seifun Group Inc - Strategy, SWOT and Corporate Finance Report Summary Nisshin Seifun Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Vilniaus Degtine AB:戦略・SWOT・企業財務分析
    Vilniaus Degtine AB - Strategy, SWOT and Corporate Finance Report Summary Vilniaus Degtine AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • APL Co Pte Ltd:企業の戦略的SWOT分析
    APL Co Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Crane Co (CR):企業の財務・戦略的SWOT分析
    Crane Co (CR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Salk Institute for Biological Studies-製薬・医療分野:企業M&A・提携分析
    Summary Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise molecular biology and genetics, neurosciences, and plant biology. Its research provides development of new therapies and treatments for di …
  • Enerflex Ltd (EFX):企業の財務・戦略的SWOT分析
    Enerflex Ltd (EFX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bet Shemesh Engines Holdings (1997) Ltd:企業の戦略・SWOT・財務情報
    Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report Summary Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Polish Oil and Gas Company (PGNiG SA):戦略・SWOT・企業財務分析
    Polish Oil and Gas Company (PGNiG SA) - Strategy, SWOT and Corporate Finance Report Summary Polish Oil and Gas Company (PGNiG SA) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • HighCom Global Security, Inc.:企業の戦略・SWOT・財務情報
    HighCom Global Security, Inc. - Strategy, SWOT and Corporate Finance Report Summary HighCom Global Security, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • University of California:製薬・医療:M&Aディール及び事業提携情報
    Summary University of California is a public research university system that offers educational and research services. The university’ services include research and teaching services, graduate, undergraduate and postgraduate courses, doctoral programs and courses, master’s programs, degree programs, …
  • Vivartia Holdings SA.:戦略・SWOT・企業財務分析
    Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report Summary Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Ohr Pharmaceutical Inc (OHRP):製薬・医療:M&Aディール及び事業提携情報
    Summary Ohr Pharmaceutical Inc (Ohr), formerly BBM Holdings Inc, is a pharmaceutical company that develops novel therapies for ophthalmic diseases. The company offers products such as squalamine lactate ophthalmic solution and SKS sustained release technology products. Its squalamine lactate ophthal …
  • ComfortDelGro Corporation Limited:戦略・SWOT・企業財務分析
    ComfortDelGro Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary ComfortDelGro Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Twenty-First Century Fox Inc. (FOXA):企業の財務・戦略的SWOT分析
    Twenty-First Century Fox Inc. (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Qioptiq Group:企業の戦略的SWOT分析
    Qioptiq Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Wolters Kluwer nv:企業の戦略・SWOT・財務情報
    Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report Summary Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Corium International Inc (CORI):医療機器:M&Aディール及び事業提携情報
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆